FDA Brief

Warning letters Drugs

FDA warning letter to

Brenntag Great Lakes, LLC

High riskIssued Oct 26, 2023Posted Nov 21, 2023Division of Pharmaceutical Quality Operations III

Brenntag Great Lakes failed to prevent cross-contamination of OTC hand sanitizer made on equipment shared with industrial chemicals.

What happened

FDA inspected the drug manufacturing facility from April 26 to May 5, 2023. The investigator found the company continued to use non-dedicated blending tanks for OTC hand sanitizer even though it had said it would stop; the same equipment was used for Class 2 solvents and industrial chemicals, including automotive brake parts cleaner. FDA also found the quality unit did not adequately oversee manufacturing, including production-record review, process controls, computer controls, and periodic product reviews.

What FDA found

  1. The company did not have or follow adequate written procedures for cleaning and maintaining equipment, and it kept making OTC hand sanitizer in non-dedicated tanks also used for industrial chemicals.

    21 CFR 211.67(b)
  2. The quality unit, the group responsible for drug quality, did not provide adequate oversight to ensure drug products met current good manufacturing practice and specifications.

    21 CFR 211.22
  3. The quality unit lacked adequate procedures for reviewing production records and ensuring errors were fully investigated.

    21 CFR 211.22(a)
  4. The company lacked adequate written production and process controls, such as mixer speed for the hand sanitizer.

    21 CFR 211.100(a)
  5. The company did not have appropriate control over computer systems.

    21 CFR 211.68(b)
  6. The company did not perform periodic product reviews.

    21 CFR 211.180(e)

What FDA wants

FDA tells Brenntag to correct the violations promptly and respond in writing within 15 working days with corrective actions and prevention plans, including confirmation or a plan for dedicated equipment and a quality unit remediation plan. If it cannot complete corrections in that time, it must state why and provide a completion schedule; FDA also recommends engaging a qualified consultant to help meet current good manufacturing practice requirements.

Who should pay attention

  • companies that buy OTC hand sanitizer or other drugs from this facility
  • drug manufacturers that share equipment with non-drug products
  • quality teams responsible for supplier and contract manufacturing oversight

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk